A series of arylketo-containing P1-P3 linked macrocyclic BACE-1 inhibitors were designed, synthesized, and compared with compounds with a previously known and extensively studied corresponding P2 isophthalamide moiety with the aim to improve on permeability whilst retaining the enzyme-and cell-based activities. Several inhibitors displayed substantial increases in Caco-2 cell-based permeability compared to earlier synthesized inhibitors and notably also with retained activities, showing that this approach might yield BACE-1 inhibitors with improved properties.
INTRODUCTION
Alzheimer's disease (AD) is a devastating neurodegenerative disorder and the most common form of dementia among the elderly. It is believed that 24 million people worldwide suffer from the disease [1] , and with an aging population the number of patients with AD is expected to rise. To develop disease-modifying drugs is therefore of paramount importance. The pathological findings associated with AD are insoluble extracellular amyloid -plaques, consisting of A -peptides, and intracellular neurofibrillary tangles found in the brain [2] . The human aspartic protease BACE-1 ( -secretase) initiates the cleavage of the amyloid precursor protein (APP) followed by -secretase which generates the A -peptides, where BACE-1 catalyzes the ratelimiting step in this sequence [3] . This, together with the knowledge that BACE-1 knockout mice are viable and fertile, suggests that inhibition of BACE-1 could be a promising therapeutic target for the treatment of AD [4, 5] . However, the development of potent and selective BACE-1 inhibitors able to cross the blood-brain barrier (BBB) and avoid Pglycoprotein (P-gp) efflux shuffling has proven to be challenging [6, 7] . Notably though, in December 2013, Merck announced that they plan to initiate a new phase III study for their BACE-1 inhibitor MK-8931. Also, in September 2014 AstraZeneca and Eli Lilly & Company announced that they will develop and commercialize AZD3293. This proves that it is possible to design and synthesize potent and selective BACE-1 inhibitors [8] .
Earlier studies in our laboratory [9] led to the development of a series of macrocyclic BACE-1 inhibitors, e.g. compound 1a (Fig. 1) , where both promising enzymatic and cell-based activities were observed. However, as these *Address correspondence to this author at the Department of Chemistry, Linköping University, S-581 83 Linköping, Sweden; Tel: +46 13 281000; Fax: +46 13 281399; E-mail: andda@ifm.liu.se inhibitors suffered from low permeability, we have in this study focused on improving the cell-based permeability by replacing the terminal amide of the P2 isophthalamide moiety with an acetophenone-type ketone group, thus rendering the molecules less peptidic (Fig. 1) . Earlier studies have shown that the amide carbonyl oxygen of the P2 isophthalamide moiety forms a hydrogen bond with Thr232 in BACE-1, whilst the amide nitrogen does not make significant interactions with the enzyme [10, 11] . Moreover, it has been shown that the amide group of the P2 isophthalamide moiety can be replaced by a carbon chain, without significant loss in potency [6, 11] , which renders the BACE-1 10s loop in a closed conformation with a hydrogen bond between Ser10 and Thr232, stabilizing the closed conformation. We thus hypothesized that an acetophenone-type carbonyl would provide an advantageous bioisostere to the amide group in this position, resulting in higher permeability through making less overall hydrogen bonds and provide inhibitors with retained good activity compared to their isophthalamide analogues. Also, further attempts to improve the cell-based permeability were performed by replacing the P2 sulfonamide functionality with a less polar methyl group. Fig. (1) . Lead compound 1a together with a general structure of the target macrocycles presented in this paper. diol 3 in 78% yield. The primary hydroxyl group in 3 was selectively tosylated using p-TsCl, Bu 2 SnO, and TEA in dry DCM [12] to generate compound 4 (74%). The tosylated compound was then converted into the corresponding epoxide 5 in 84% yield, using K 2 CO 3 in MeOH. The epoxide was thereafter opened with 3-isopropylbenzylamine furnishing compound 6 in 56% yield. For purification reasons, the prepared amine was protected using Boc 2 O and TEA in MeOH to give compound 7 (81%). Finally, the azide 7 was reduced using 1,3-propanedithiol, TEA, and Aliquat 336 in MeOH to afford the amine 8 in 76% yield.
The synthesis of compounds 18a, 18b, and 19 is depicted in Scheme 2. 2,3-O-Isopropylidene-D-glyceraldehyde was synthesized according to a literature procedure [13] and the addition of a freshly prepared Grignard reagent, pent-4enylmagnesium bromide or hex-5-enylmagnesium bromide, produced the two compounds 9a and 9b in diastereomeric mixtures which were subsequently separated. In the case of 9b we had enough material of the correct diastereomer after the chromatography separation to proceed directly to 12b. (The various stereoisomers were identified by NMR analyses). The hydroxyl group in (S,R)-9a was reacted with PPh 3 , DIAD, and p-nitrobenzoic acid in THF, furnishing compound 10a in 91% yield. The benzoate ester was cleaved using NaOMe in MeOH to give the inverted alcohol 11a in 68% yield. Mitsunobu conditions, utilizing DPPA [14] , generated the azide 12a with inversion of configuration in 98% yield. The acetal in 12a was hydrolyzed in AcOH (aq.) at 60 °C (74%) and the primary alcohol in the formed diol 13a was selectively tosylated, using TEA, Bu 2 SnO, and p-TsCl in DCM and DMF, to give compound 14a in 84% yield. The epoxide 15a was prepared in 90% yield using Na 2 CO 3 in MeOH, and was then opened with 3-isopropylbenzylamine and TEA in MeOH at 30 °C to give compound 16a (61%). Compound 16b was synthesized, with comparable yields, in the same manner from 12b. Finally, reduction of the azide group in compounds 16a, 16b, and 17 was achieved using 1,3-propanedithiol, TEA, and Aliquat 336 in MeOH, providing the amines 18a and 18b in 83% and 81% yield, respectively. As an alternative synthetic route, for purification reasons, compound 16a was treated with Boc 2 O and TEA in MeOH to afford the Boc-protected compound 17 in 97% yield. 17 was then reduced as above, yielding 19 (88 %).
The synthesis of target compounds 28a and 28b is outlined in Scheme 3. The compounds were synthesized using two slightly different routes, depending on if the amine (see Scheme 2) was Boc-protected before the peptide coupling step or after. Compound 20a was synthesized according to a reported procedure [15] and the carboxylic acid was selectively reduced with BH 3 ·SMe 2 in dry THF to give the alcohol 21a in 95% yield. A Parikh-Doering oxidation [16] generated the aldehyde 22a (95%) and the subsequent addition of the Grignard reagent pent-4-enylmagnesium bromide furnished the alcohol 23a in 65% yield. This compound was oxidized to the corresponding ketone 24a in 76% yield using Dess-Martin periodinane in DCM [17] . The ester functionality in 24a was hydrolyzed using aqueous LiOH in dioxane and the resulting carboxylic acid was coupled with compound 19 using HATU and DIPEA in DMF to afford compound 25a in 89% yield over two steps. Compound 25b was synthesized in the same manner as 25a using commercially available 20b instead of 20a, and amine 18a instead of 19 in the coupling reaction. For purification reasons, the amino group in compound 25b was protected using Boc 2 O and TEA in MeOH to give compound 26 in 69% yield. A ringclosing metathesis protocol was performed on compound 25a and 26 using Hoveyda-Grubbs 2 nd generation catalyst in refluxing DCM to furnish the macrocyclic compounds 27a and 27b in 21% and 47% yield, respectively. The cyclization resulted in exclusive formation of the trans isomers, as confirmed by 1 H-NMR analyses. Finally, deprotection of the Boc group was achieved with Et 3 SiH and TFA in DCM to give the two target compounds 28a and 28b in 91% yield in both cases. Targets 34 and 35 (see Table 1 ) were synthesized according to the same synthetic route as 28a, using amine 8 instead of 19 and the methyl ester 24b instead of 24a for compound 35. Target 36 (see Table 1 ) was synthesized in the same manner as 28b using amine 18b instead of 18a.
When using the route described in Scheme 3, the ringclosing metathesis step was unsuccessful when trying to synthesize target 33 (see Table 1 ). The reason for this is at this stage unknown. Therefore, a different synthetic route was outlined for 33, as shown in Scheme 4. The methyl ester functionality in compound 24b was hydrolyzed using LiOH (aq.) in dioxane/H 2 O to furnish the corresponding carboxylic acid, which was subsequently used in a peptide coupling step with the amine (S)-2-(allyloxy)-1-((S)-2,2-dimethyl-1,3dioxolan-4-yl)ethanamine [9] using HATU and DIPEA in DMF to give compound 29 in 57% yield. The acetal was hydrolyzed with 80% AcOH to generate the diol 30 in 95% yield. The ring-closing metathesis protocol, using Hoveyda-Grubbs 2 nd generation catalyst in refluxing DCM, was now successful and rendered the macrocycle 31 in 88% yield. The primary hydroxyl group in 31 was tosylated by the use of TEA, Bu 2 SnO, and p-TsCl in DCM and DMF, which furnished compound 32 (57%). Finally, the tosylated compound was reacted with the amine 2-(5-(tert-butyl)oxazol-2yl)propan-2-amine (see supp. info.) and DIPEA in refluxing EtOH to give the target compound 33 in 5% yield.
Structure Activity Relationships
All target compounds were screened against BACE-1, both in enzyme-and cell-based assays, and the IC 50 values are shown in Table 1 , along with Caco-2 p app values for selected compounds. The macrocycles were all 15-membered, except for compound 36 which was 16-membered.
Replacement of the terminal P2 amide functionality in the lead compound 1a [9] with a keto group resulted in target product 34 which showed retained potencies against BACE-1 although without displaying improved permeability. It has earlier been found that BACE-1 inhibitors with a sulfonamide substituted isophthalamide in the P2 position are substrates for P-gp efflux [18] , which could explain the low permeability of compound 34. Replacement of the P2 sulfonamide functionality with a less polar methyl group furnished compound 35, resulting in a significantly improved (p app = 13 x 10 -6 cm/s) permeability. However, with the P2 sulfonamide replaced with a methyl group the BACE-1 activity was substantially reduced, but this compound exhibited comparable BACE-1 activities as the amide analogue 1b [9] ( Table 1) published earlier (a BACE-1 IC 50 value of 1100 vs. 500 nM and a cell-based IC 50 value of 1400 vs. 220 nM, respectively), but with significantly better permeability (a Caco-2 value of 13 x 10 -6 cm/s, as mentioned above, vs. < 1 x 10 -6 cm/s, respectively). In-house studies have shown that the introduction of a oxazole group (see supplementary material) in the P2´ position can give rise to highly active compounds and with improved permeability. Introduction of this oxazole group provided compound 33 which exhibited additional improvement in permeability compared with inhibitor 35 whilst retaining enzyme-and cell-based activity compared with compound 35. The X-ray structure of 33 (PDB id: 4GMI) in complex with BACE-1 shows that the gem-methyl groups shielding the secondary nitrogen atom are well accommodated for and, as such, are not exerting any steric impediment on compound binding (Fig. 2) . Moreover, the P2' tert-butyl substituted oxazole has a good fit to the S2' subsite, including a hydrogen bond to Thr72 of the flap.
Generally, we have noted that replacing the macrocyclic ether oxygen with a carbon in these inhibitors often results in increased potency [19] . However, the carbon analogue to compound 34, inhibitor 28a, showed similar potent activities (a BACE-1 IC 50 value of 8.9 vs. 12 nM and a cell-based IC 50 value of 3.0 vs. 4.6 nM, respectively). As expected, with a P2 sulfonamide moiety, compound 28a also displayed a similar low Caco-2 permeability value (< 1 x 10 -6 cm/s). As foreseen, the Boc-protected compound 27b was inactive. (It is well established that hydroxyethylamine-based BACE-1 inhibitors bind to the catalytic aspartates Asp32 and Asp228 via the protonated amino and hydroxy groups [9, 20, 21] ). Compound 28b, incorporating a toluene core in the P2 position, displayed an improved potency compared to its analogue 35 (IC 50 280 vs. 1100 nM, respectively) and equal permeability (p app = 13 x 10 -6 cm/s). The 16-membered macrocycle 36 showed similar activity and permeability as its corresponding 15-membered macrocycle 28b. Attempts to synthesize the corresponding 14-membered macrocycle were unsuccessful, likely due to a high ring strain of the target product.
CONCLUSION
A novel series of macrocyclic BACE-1 inhibitors incorporating a P2/P3 keto functionality was investigated, with some inhibitors showing highly promising low nanomolar activities against the BACE-1 enzyme and in the cell-based assay. Moreover, several inhibitors exhibited improved cellbased permeability compared to inhibitors previously synthesized, but, not unexpectedly, these target compounds displayed decreased potency due to replacement of the sulfonamide functionality in the P2 position with a methyl group, where the sulfonamide moiety has been shown to be important for the activity in this type of inhibitor compounds. In summary, improved permeability could be achieved compared to earlier published inhibitors from our group whilst retaining the overall BACE-1 inhibitory activities.
Further work on this series is highly warranted exploring sulfonamide replacements in the P2-position, e.g. by use of small lipophilic groups and by introducing potencyenhancing lipophilic substituents protruding into the S3 sub pocket.
EXPERIMENTAL SECTION
General NMR-spectra were recorded on a Varian 300 MHz instrument using CDCl 3 , CD 3 OD or DMSO-d 6 as solvents. Thin layer chromatography (TLC) was carried out on Merck precoated 60 F 254 plates using UV-light and charring with ethanol/sulfuric acid/p-anisaldehyde/acetic acid 90:3:2:1, or a solution of 0.5% ninhydrin in ethanol, for visualization. Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Organic phases were dried over anhydrous magnesium sulfate. Optical rotations were measured using a Perkin-Elmer 141 polarimeter at 22 °C. Gradient LC-MS was performed on a Gilson system (column: Phenomenex C18, 100 x 21 mm, 5 m for preparative runs and xBridge TM C18, 50 x 4.6 mm, 2.5 μm for analytical runs; pump: Gilson gradient pump 322; UV/VIS-detector: Gilson 152; MS detector: Thermo Finnigan Surveyor MSQ; Gilson Fraction Collector FC204) using acetonitrile with 0.05% formic acid and deionized water with 0.05% formic acid as mobile phases. High resolution mass spectra (HRMS) were recorded on a Waters Synapt HDMS instrument equipped with an electrospray interface.
BACE-1 Enzyme Assay
The BACE-1 assay was performed as previously described [22] .
BACE-1 Cell Assay
The cell-based assay was performed as previously described [23] .
Caco-2 Assay
The permeability coefficients (p app ) were performed as previously described [24] . (2S,3S)-4-(Allyloxy)-3-azido-2-hydroxybutyl 4-methyl benzenesulfonate (4). TEA (830 μL, 6.0 mmol), Bu 2 SnO (124 mg, 0.5 mmol) and p-TsCl (1.13 g, 5.9 mmol) were added to a solution of compound 3 (930 mg, 4.9 mmol) in dry DCM (30 mL). The mixture was stirred for 3.5 hours at room temperature. The solution was thereafter diluted with DCM, washed two times with brine and the organic phase was dried, filtered and concentrated. Purification using flash column chromatography (toluene/EtOAc 19:1) gave compound 4 (1.25 g, 74%) as a colorless oil. 1 No mass peak could be detected.
LC-MS Purity Measurements

(S)-2-((S)-2-(Allyloxy)-1-azidoethyl)oxirane (5).
Compound 4 (1.25 g, 3.7 mmol) was dissolved in MeOH (28 mL). K 2 CO 3 (830 mg, 6.0 mmol) was added at 0 °C and the solution was left to reach room temperature and stirred for 3 hours. H 2 O and DCM were added and the organic phase was dried, filtered and concentrated. The crude material was purified using flash column chromatography (toluene/EtOAc 19:1) and compound 5 (521 mg, 84%) was collected as a colorless oil. 1 
(S)-4-((S)-1-Azidohex-5-en-1-yl)-2,2-dimethyl-1,3dioxolane (12a).
To a solution of 11a (993 mg, 4.97 mmol) in dry THF (30 mL), Ph 3 P (2.06 g, 7.85 mmol) was added and the temperature was lowered to -5 °C. DIAD (1.60 mL, 8.13 mmol) and DPPA (2.17 g, 7.89 mmol) were added dropwise during 20 min and 5 min, respectively, and the stirred solution was allowed to reach room temperature overnight. After evaporation of the solvent the crude mixture was purified using flash column chromatography (2.5% EtOAc in heptane) to give 12a (1.10 g, 98%) as a slightly yellow oil. 1 Hz, 2H); 13 C-NMR (CDCl 3 , 75.5 MHz): 21.8, 25.5, 28.7, 33.6, 63.7, 71.1, 71.7, 114.9, 128.2, 130.2, 132.6, 138.5, 145.5 . MS-analysis resulted in decomposition. No mass peak could be detected.
(S)-2-((S)-1-Azidohex-5-en-1-yl)oxirane (15a).
Compound 14a (320 mg, 0.94 mmol) was dissolved in MeOH (10 mL) and the temperature of the solution was lowered to 0 °C. Na 2 CO 3 (175 mg, 1.65 mmol) was added and the stirred mixture was allowed to obtain room temperature overnight. Saturated NH 4 Cl was added and the resulting mixture was extracted with DCM. The organic phase was dried, filtered and evaporated and the crude remainder was purified using flash column chromatography (toluene) to provide the somewhat volatile 15a (157 mg, 100%) as a colorless oil. Butyl ((2R,3S)-3-azido-2-hydroxyoct-7-en-1-yl) (2R,3S)-3-Amino-1-((3-isopropylbenzyl) amino)oct-7en-2-ol (18a). To a solution of 16a (115 mg, 0.36 mmol) in MeOH (1.5 mL), TEA (250 L, 1.79 mmol), 1,3propanedithiol (180 L, 1.79 mmol) and Aliquat 336 (2 drops) were added. The solution was stirred at room temperature for 5 days, after which 1 M HCl, H 2 O and DCM were added. The aqueous phase was washed with DCM and was then made basic with 1 M NaOH. Subsequently, the water phase was extracted with EtOAc and the organic phase was dried, filtered and evaporated to yield 18a (88 mg, 83%) as a colorless oil. 1 
tert-
tert-Butyl ((2R,3S)-3-amino-2-hydroxyoct-7-en-1-yl) (3-isopropylbenzyl)carbamate (19).
Compound 19 (151 mg, 88%) was synthesized in the same manner as 18a from 17 and was collected as a colorless oil. 1 mmol) in THF (30 ml, dry) was flushed with Ar at 0°C. After 10 minutes BH 3 SMe 2 (930 μL, 9.81 mmol) was added slowly and the mixture was left to reach room temperature and was stirred under Ar for 24 hours. The mixture was quenched with MeOH, concentrated, re-dissolved in EtOAc, washed with NaHCO 3 (sat. aq.) and brine. The organic phase was dried, filtered and concentrated. Finally, purification using flash column chromatography (toluene/EtOAc 3:1) gave compound 21a (1.49 g, 95%) as white crystals. 1 Methyl 3-(1-hydroxyhex-5-en-1-yl)-5-methylbenzoate (23b). Compound 23b (580 mg, 79%) was synthesized from 22b in the same manner as 23a and was collected as a colorless oil. 1 
tert-Butyl
((2R,3S)-3-(3-(hex-5-enoyl)-5-(N-methylmethylsulfonamido)benzamido)-2-hydroxyoct-7-en-1yl)(3-isopropylbenzyl)carbamate (25a). Aqueous LiOH (40 mg/mL, 324 L, 0.54 mmol) was added to a solution of 24a (61 mg, 0.18mmol) in a mixture of dioxane (10 mL) and water (5 mL) and the solution was stirred at room temperature for 2 h. After neutrilization with 1 M HCl, the volatiles were evaporated and the crude remainder was dissolved in DMF (10 mL). DIPEA (105 L, 0.60 mmol) and compound 19 (46 mg, 0.12 mmol) were added and the temperature was lowered to 0 °C. HATU (59 mg, 0.16 mmol) was added and the solution was allowed to obtain room temperature overnight. The DMF was subsequently evaporated and the crude product was purified using flash column chromatography (toluene/EtOAc 3:1 toluene/EtOAc 1:1) to give 25a (73 mg, 89% over two steps) as a colorless glue. 1 
3-(Hex-5-enoyl)-N-((2R,3S)-2-hydroxy-1-((3-isopropylbenzyl)amino)oct-7-en-3-yl)-5-methylbenzamide (25b).
Compound 25b (117 mg, 85% over two steps) was synthesized from 24b in the same manner as 25a using amine 18a instead of 19 and was collected as a white solid. [ ] D +0.5 (c 0.1, MeOH). 1 Butyl ((2R,3S)-3-(3-(hex-5-enoyl) [(R)-2-Hydroxy-2-((E)-(S)-16-methyl-2,13-dioxo-3-azabicyclo[12.3.1]octadeca-1(17),8,14(18),15-tetraen-4-yl 4-[(R)-1-Hydroxy-2-(3-isopropyl-benzyla N-((S)-2-(Allyloxy)-1-((S)-2,2-dimethyl-1,3-dioxolan- 
tert-
N-{(E)-(S)-
4-yl)ethyl)-3-(hex-5-enoyl)-5-methylbenzamide (29).
Compound 24b (31 mg, 0.12 mmol) was dissolved in di-oxane/H 2 O (2:0.5 mL) and aqueous LiOH (40 mg/mL, 150 μL, 0.25 mmol) was added. The reaction mixture was stirred at room temperature for 6 h and then co-evaporated with toluene. The crude material was re-dissolved in DMF (1 mL) and (S)-2-(allyloxy)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine (21 mg, 0.10 mmol), HATU (71 mg, 0.18 mmol) and DIPEA (65 μL, 0.37 mmol) were added. The reaction mixture was stirred at room temperature for 4 h, evaporated and purified using flash column chromatography (toluene/EtOAc 3:1) to give compound 29 (25 mg, 57%) as a colorless oil. 1 -1(18),8,14,16-tetraene-2,13-dione 
N-((2S,3S)-1-(Allyloxy)-3,4-dihydroxybutan-2-yl)-3-
